Psilocybin may not be legal for most of the U.S., but that could change. All thanks to mounting evidence that shows the drug may be beneficial in treating mental health issues. In fact, recent results from a Johns Hopkins University study revealed the drug could produce sustainable anti-depressant effects. A study in the journal, Nature — Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms – showed that 47% of treatment-resistant patients with depression showed positive responses five weeks after psilocybin treatments. In addition, companies like NeonMind Biosciences Inc. (CSE: NEON) are studying its potential impact on weight loss and obesity. That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."
Other companies researching potential positives of psilocybin include Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Tryp Therapeutics Inc. (CSE:TRYP), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), and Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF).
NeonMind Biosciences Inc. (CSE: NEON), BREAKING NEWS : NeonMind Biosciences Inc., a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms, is pleased to announce that it has added Frank Russo as an advisor and consultant to assist the Company in selecting or developing music playlists for its clinical trials or for use with treatments to support optimum mental health.
Frank Russo is a professor of Psychology at Ryerson University. He is also an affiliate scientist at the Toronto Rehabilitation Institute, core member of the McMaster Institute for Music and the Mind (MIMM), and adjunct professor at the University of Toronto’s Music and Health Collaboratory (MaHRC). In his Science of Music Auditory Research and Technology (SMART) Lab at Ryerson, he conducts basic research on the biological, cognitive, and social-emotional bases of music and speech. His work tends to be interdisciplinary in nature but is most closely aligned with the academic disciplines of perceptual science, cognitive science, emotion science, and neuroplasticity. He is a Fellow of the Canadian Psychological Association and Massey College, and is a past president of the Canadian Acoustical Association.
He also engages in two related areas of applied research. The first area seeks to develop and optimize assistive and rehabilitative technologies that may support perception and production of vocal-facial emotion. The second area assesses the potential for music-based interventions to contribute to health and wellbeing.
“Dr. Russo is an expert working at the intersection of brain health, psychology and music,” said Penny White, CEO of NeonMind. “He will assist our team in examining the intersection between psychedelics and music, the neurological impact of both and related therapeutic implications.”
Dr. Russo will assist NeonMind in developing effective protocols for psychedelic treatments that incorporate music as part of the treatment in human clinical trials to be submitted for approval to Health Canada. He will also assist NeonMind in building alliances and partnerships in the music industry, and establish one or more multi-party projects to further develop data that can support the use of music to enhance mental health and treat drug addiction.
“I am excited to have the opportunity to work with NeonMind on exploring this groundbreaking area of cognitive science,” said Frank Russo. “Music has such a transformative effect on the brain, and I can foresee its potential to enhance the results that are achievable with psychedelic therapy as well.”
Other related developments from around the markets include:
Cybin Inc. (NEO:CYBN)(OTC:CLXPF), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to provide an update on its eight patent filings , which cover the Company’s novel therapeutics, delivery mechanisms and treatment regiments. The Company is also pleased to announce that it intends to expand the development of its therapeutics program to include, in addition to psilocybin, psychedelic compounds such as DMT, psilocybin analogues and a range of tryptamines and phenylethylamines which are expected to have improved pharmacokinetic profiles, while retaining the efficacy of the original molecules. In addition, the Company intends to build a database of molecules and their chemically synthesized pathways for use in the pharmaceutical industry. “Our management team has a proven track record in developing and commercializing dozens of therapeutics, including a modified psychedelic targeted for treatment resistant depression and we intend to continue to advance our IP portfolio, drug discovery platform, delivery mechanisms and technologies all with the end goal of enhancing the patient experience and progressing the psychedelic industry,” said Cybin’s Chief Executive Officer, Doug Drysdale.
Tryp Therapeutics Inc. (CSE:TRYP) a clinical-stage pharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, announced it has entered into an agreement with Albany Molecular Research Inc., a leading global contract research, development and manufacturing organization, to provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs. “Working with AMRI as our U.S.-based active pharmaceutical ingredient supplier is a critical component of our rapid clinical development strategy and we very pleased to have engaged them to support our neuropsychiatric programs. By working with AMRI, we are able to create additional intellectual property around the manufacture and use of our proprietary psilocybin API.” said Larry Norder, Vice President of Manufacturing of Tryp. Mr. Norder further commented, “AMRI’s excellent industry reputation, size, and wealth of experience with manufacturing API under cGMP brings very high credibility to our efforts to develop psilocybin as a therapeutic for indications with high unmet medical needs.”
Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF) is pleased to announce that it has closed its previously announced bought deal short form prospectus offering , including the exercise in full of the Underwriters’ over-allotment option. In connection with the Offering, the Company issued 20,930,000 units of the Company at a price per Unit of CAD $4.40 for gross proceeds of approximately CAD $92.1m. The Offering was conducted by Canaccord Genuity Corp., along with Eight Capital and CIBC Capital Markets.
Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), one of the leaders in the development and delivery of psychedelic therapies, announced that it is in advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with psilocybin therapies following the passage of Measure 109. Measure 109, which was approved by voters in Oregon on November 3, 2020, requires the Oregon Health Authority to create a licensing system that will create a regulated program for the cultivation of psilocybin-producing mushrooms and the provision of supervised psilocybin therapy, effectively creating the first legal market for psilocybin therapies in North America.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Inc. Please click here for full disclaimer.
Contact Information:
2818047972
ty@LifeWaterMedia.com